Top

Published in:

01-11-2012 | Original Article

A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma

Authors: Zarah Glad Zimling, Jens Benn Sørensen, Thomas Alexander Gerds, Cecilia Bech, Claus Bøgelund Andersen, Eric Santoni-Rugiu

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2012

Abstract

Purpose

Malignant pleural mesothelioma (MPM) has a dismal prognosis. Treatment results may be improved by biomarker-directed therapy. We investigated the baseline expression and impact on outcome of predictive biomarkers ERCC1, BRCA1, and class III β-tubulin in a cohort of MPM patients treated with cisplatin–vinorelbine. We further explored the possibility of combining markers into a treatment-response profile to increase the predictive power.

Methods

Formalin-fixed paraffin-embedded tumor specimens from 54 MPM patients included in a phase II trial were evaluated for ERCC1, BRCA1, and class III β-tubulin by immunohistochemistry (IHC). Immunostaining was quantified by an H-score and dichotomized according to upper quartile values. The ERCC1- and class III β-tubulin-status classified patients as treatment resistant (ERCC1 positive + class III β-tubulin positive) or treatment responsive (ERCC1 negative + class III β-tubulin negative). The remaining marker combinations were considered inconclusive.

Results

Fifty patients had tumor tissue available for IHC. Eleven had a responsive profile, and nine had a resistant profile. Thirty patients had an inconclusive profile. Median progression-free survival (PFS) was 6.7 months in the treatment-resistant group, 15.3 months in the treatment-responsive group, and 8.1 months in the inconclusive group (log-rank p = 0.03). Multivariate analysis revealed that treatment-resistant patients had a decreased PFS and overall survival (OS) compared with the treatment-responsive patients (HR 6.45, CI 95 % [2.02–20.64] p = 0.002 and HR 4.64, CI 95 % [1.56–13.79], p = 0.006, respectively). BRCA1 status was associated with neither PFS nor OS.

Conclusion

Combined negative ERCC1 and class III β-tubulin immunostaining is associated with significantly prolonged PFS and OS in MPM patients receiving cisplatin–vinorelbine therapy.

Churg A, Roggli V, Galateau-Salle F et al (2004) Mesothelioma. In: Travis WD, Brambilla E, Müller-Hermelink HK et al (eds) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC press, Lyon, pp 128–136

Sorensen JB (2008) Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J 2:74–79PubMedCrossRef

Carlson RW, Allred DC, Anderson BO et al (2009) Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7:122–192PubMed

Gridelli C, De MF, Di MM et al (2011) Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: review of the evidence. Lung Cancer 71:249–257PubMedCrossRef

Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712PubMedCrossRef

Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865PubMedCrossRef

Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279PubMedCrossRef

Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14:1291–1295PubMedCrossRef

Vilmar AC, Santoni-Rugiu E, Sorensen JB (2010) ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 21:1817–1824PubMedCrossRef

10.

Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef

11.

Steffensen KD, Waldstrom M, Jakobsen A (2009) The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 19:820–825PubMedCrossRef

12.

Kim KH, Do IG, Kim HS et al (2010) Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 118:941–948PubMedCrossRef

13.

Kennedy RD, Quinn JE, Mullan PB et al (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659–1668PubMedCrossRef

14.

Cass I, Baldwin RL, Varkey T et al (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187–2195PubMedCrossRef

15.

Taron M, Rosell R, Felip E et al (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13:2443–2449PubMedCrossRef

16.

Tassone P, Blotta S, Palmieri C et al (2005) Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol 26:1257–1263PubMed

17.

Stordal B, Davey R (2009) A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets 9:354–365PubMedCrossRef

18.

Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221–6228PubMed

19.

Mullan PB, Gorski JJ, Harkin DP (2006) BRCA1–a good predictive marker of drug sensitivity in breast cancer treatment? Biochim Biophys Acta 1766:205–216PubMed

20.

Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10:194–204PubMedCrossRef

21.

Gan PP, Pasquier E, Kavallaris M (2007) Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67:9356–9363PubMedCrossRef

22.

Seve P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9:168–175PubMedCrossRef

23.

Seve P, Isaac S, Tredan O et al (2005) Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481–5486PubMedCrossRef

24.

Seve P, Mackey J, Isaac S et al (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001–2007PubMedCrossRef

25.

Vilmar AC, Santoni-Rugiu E, Sorensen JB (2011) Class III {beta}-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 17:5205–5214PubMedCrossRef

26.

Tommasi S, Mangia A, Lacalamita R et al (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer 120:2078–2085PubMedCrossRef

27.

Seve P, Reiman T, Lai R et al (2007) Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60:27–34PubMedCrossRef

28.

Zimling ZG, Sorensen JB, Gerds TA et al (2012) Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 7:249–256PubMedCrossRef

29.

Sorensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99:44–50PubMedCrossRef

30.

Rusch VW (1996) A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14:1–12PubMedCrossRef

31.

Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257–260PubMedCrossRef

32.

Francart J, Legrand C, Sylvester R et al (2006) Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma—The EORTC Lung Cancer Group. J Clin Oncol 24:3007–3012PubMedCrossRef

33.

Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef

34.

Marquis ST, Rajan JV, Wynshaw-Boris A et al (1995) The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11:17–26PubMedCrossRef

35.

Yoshikawa K, Honda K, Inamoto T et al (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 5:1249–1261PubMed

36.

Cicchillitti L, Penci R, Di MM et al (2008) Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol Cancer Ther 7:2070–2079PubMedCrossRef

37.

D’Addario G, Fruh M, Reck M et al (2010) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v116–v119PubMedCrossRef

38.

Ohishi Y, Oda Y, Basaki Y et al (2007) Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 105:586–592PubMedCrossRef

39.

Reiman T, Lai R, Veillard AS et al (2012) Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23:86–93PubMedCrossRef

40.

Ikeda S, Takabe K, Suzuki K (2009) Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 59:863–867PubMedCrossRef

41.

Azuma K, Sasada T, Kawahara A et al (2009) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326–333PubMedCrossRef

42.

Steele JP, Shamash J, Evans MT et al (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912–3917PubMed

43.

Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323–1327PubMedCrossRef

44.

Gustavson MD, Bourke-Martin B, Reilly D et al (2009) Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med 133:1413–1419PubMed

Title: A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma
Authors: Zarah Glad Zimling
Jens Benn Sørensen
Thomas Alexander Gerds
Cecilia Bech
Claus Bøgelund Andersen
Eric Santoni-Rugiu
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 5/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1965-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors

Phase I trial of pomalidomide given for patients with advanced solid tumors

Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer

Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity

A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer

Erratum to: The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response

Keynote webinar | Spotlight on antibody–drug conjugates in cancer